These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 22450313

  • 1. Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
    Gu JL, Li J, Zhou ZH, Liu JR, Huang BH, Zheng D, Su C.
    Biochem Biophys Res Commun; 2012 Apr 13; 420(3):644-50. PubMed ID: 22450313
    [Abstract] [Full Text] [Related]

  • 2. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
    Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC.
    Cancer Res; 2001 Apr 01; 61(7):3071-6. PubMed ID: 11306489
    [Abstract] [Full Text] [Related]

  • 3. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, Horvath N, Ho PJ, Harrison S, Fleming S, Joshua DE, Allen JD.
    Haematologica; 2012 Jan 01; 97(1):64-72. PubMed ID: 21993678
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, Perez LE, Dalton WS, Beaupre DM.
    Clin Cancer Res; 2006 Jan 15; 12(2):591-9. PubMed ID: 16428505
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 11. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
    Chauhan D, Li G, Auclair D, Hideshima T, Podar K, Mitsiades N, Mitsiades C, Chen LB, Munshi N, Saxena S, Anderson KC.
    Apoptosis; 2004 Mar 21; 9(2):149-55. PubMed ID: 15004512
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P, Galán-Malo P, Marzo I, Naval J.
    Leuk Res; 2012 Feb 21; 36(2):212-8. PubMed ID: 21978467
    [Abstract] [Full Text] [Related]

  • 13. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.
    Biochem Pharmacol; 2009 Mar 01; 77(5):804-12. PubMed ID: 19100720
    [Abstract] [Full Text] [Related]

  • 14. [Effects of xbp-1 gene silencing on bortezomib-induced apoptosis in human multiple myeloma cells].
    Yang Y, Dong HJ, Gao GX, Wang YW, Gu HT, Shu MM, Zhu HF, Chen XQ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct 01; 18(5):1177-80. PubMed ID: 21129256
    [Abstract] [Full Text] [Related]

  • 15. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W, Chen J, Chuang M, Jiang D.
    APMIS; 2012 Mar 01; 120(3):195-203. PubMed ID: 22339676
    [Abstract] [Full Text] [Related]

  • 16. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.
    Cancer Res; 2007 Jun 01; 67(11):5418-24. PubMed ID: 17545623
    [Abstract] [Full Text] [Related]

  • 17. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
    Ju D, Xie Y.
    Mol Med Rep; 2014 Nov 01; 10(5):2609-12. PubMed ID: 25174315
    [Abstract] [Full Text] [Related]

  • 18. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D, McConnell EJ, Dierlam L, Palamarchuk A, Lass A, Wójcik C.
    Int J Cancer; 2007 Jul 15; 121(2):431-41. PubMed ID: 17373661
    [Abstract] [Full Text] [Related]

  • 19. [Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
    Iida S, Ri M.
    Rinsho Ketsueki; 2014 Mar 15; 55(3):304-10. PubMed ID: 24681933
    [No Abstract] [Full Text] [Related]

  • 20. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.
    Song IS, Kim HK, Lee SR, Jeong SH, Kim N, Ko KS, Rhee BD, Han J.
    Int J Cancer; 2013 Sep 15; 133(6):1357-67. PubMed ID: 23463417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.